Mind maps Thalassaemia Flashcards
What is it
Genetic conditions, inherited in an autosomal recessive pattern, the produce a picture of microcytic anaemia due to a problem in globin chain production.
This subsequently alters haemoglobin synthesis.
Types
Alpha-thalassaemia
Beta-thalassaemia
Populations affected by alpha thalassaemia
More prominent in African and Asian populations
Causes of alpha thalassaemia
Decreased Alpha-Globin (a-globin) synthesis due to a-globin gene mutation on chromosome 16
This results in excess Beta-globin (b-globin) production
Variation in cause of a-thalassaemia
Any number between 1 and 4 genes may be deleted: 1 gene deleted = no significant anaemia 2 = trait disease 3 = HbH disease 4 = death - Bart's hydrops fetalis
Populations affected by beta thalassaemia
More prominent in European populations
Causes of b-thalassaemia
Point mutation in beta-globin chain on chromosome 11
Results in excess a-globin production
3 traits that b-thalassaemia can be subdivided into
Minor = usually asymptomatic; carrier state; mild anaemia Intermediate = moderate anaemia; no blood transfusions required Major = Cooley's anaemia; abnormalities in all b-globin chains results in severe anaemia
What sign is characteristic of major beta-thalassaemia
Cranial bossing seen due to extramedullary haematopoiesis
What type of anaemia is thalassaemia
Microcytic, hypochromic
Investigations for either alpha or beta thalassaemia
Blood films (target cells may be seen in alpha)
FBC
Hb electrophoresis
High performance liquid chromatography
Radiology - X-ray for bone abnormalities e.g. frontal bossing
What is expected on Hb electrophoresis of thalassaemia
High HbA2
High HbF
What is assessed/expected on FBC of thalassaemia
Microcytic, hypochromic anaemia Low MCV Low MCH Ferritin normal Iron normal
Conservative treatment
Patient education
Genetic counselling
Medical treatment
Management of a or b is based on patient symptoms and overall state of health
Transfusions are usually required with Hb <7g/dL or when patient is highly symptomatic
Patients who have repeated blood transfusions are at risk of haemochromatosis and therefore iron chelation therapy